May 1, 2019: EPI investigator, and College of Liberal Arts and Sciences mathematics professor, Burton Singer has developed a model describing the spatial dynamics of Ebola transmission and the efficacy of its vaccine.
Early implementation of the Ebola vaccine is critical to slow the spread of the disease: A delay of just one week can drastically reduce the efficacy of the vaccine in highly populated areas, a new University of Florida study shows.
The Ebola outbreak in the Democratic Republic of the Congo is raging — 900 people have died in the last nine months. The epidemic began last August with 1,340 confirmed and probable cases recorded. Considerable assistance in containment has been facilitated by administration of recently developed vaccine against the Ebola virus.
The push for an Ebola vaccine was accelerated by the 2013–16 outbreak in West Africa. A phase III trial conducted there proved especially promising. The vaccine was given to 4,539 people who showed no signs of the disease. The control group with 4,557 participants reported only 16 infections.
According to data released by the World Health Organization earlier this month, the experimental Ebola virus vaccine has been remarkably effective in the DRC, providing protection against the deadly disease 97.5 percent of the time.
This photomicrograph of human liver tissue infected with the Ebola virus depicts the hepatic histopathologic changes that occur due to this illness. Read more here.
Burton Singer, an adjunct professor in UF's Emerging Pathogens Institute and the College of Liberal Arts and Sciences mathematics department, led a study to determine the spatial dynamics of Ebola transmission and to gauge the efficacy of the vaccine.
Singer says: “We developed a spatial model on a grid with slightly less than two square kilometer units and where the probability of infection in any unit depends on the infection status of other units, distance from a given unit to other infected units in the DRC, population density and poverty level of the unit. The model was calibrated using data on number and location of Ebola cases over time as given in reports from the World Health Organization.”
Using this spatial model, Singer and his colleagues discovered the risk for Ebola infection was dramatically marked in areas reporting the disease with increased risks for areas with a high population density and poverty level. The study, reported today in PNAS, focused on vaccination programs and the timeliness of the dissemination of the vaccine.
“Indeed, the rapid dissemination of the vaccine contracted the geographical area at risk for Ebola by 70.4 percent and reduced the level of risk of spread within the rural region of the outbreak by 70.1 percent. A delay of just one week in vaccine distribution would have reduced these percentages to 33.3 and 44.8, respectively,” Singer says.
Ebola remains a vital concern, not just for the DRC or other African countries, but also around the world. Cases reported in the U.S. are minimal — only 11 during the 2014–16 outbreak — resulting from someone who had traveled in West Africa. Understanding how the disease spreads and how the vaccine can be used to its highest potential is a concern for the populations most at risk, the epidemiologists who study the disease and for the health workers and medical professionals who treat it.
“The primary message from our study is the critical need for rapid dissemination of an effective Ebola vaccine,” Singer notes. “The challenge of doing this in the DRC, looking ahead, is seriously exacerbated by the proliferation of violence in the country and the consequential prevention of vaccine delivery.”
Written by Gigi Marino for UF News and originally published here on April 29, 2019. Reposted to EPI's website with light edits on May 1.
Both photos courtesy of the CDC Public Health Image Library. Top image: a public service poster photographed during Liberia's Ebola outbreak in 2014 to disseminate an educational message that hand washing would help to protect people against the spread, and acquisition, of the Ebola virus.
Read Burton Singer's EPI profile here.
Read about EPI's contributions to Ebola vaccine trials here.